Three studies presented today at the Society of NeuroInterventional Surgery's (SNIS) 22nd Annual Meeting discussed whether ...

Benefits were most prominent among women, patients older than 60 and those with a body mass index of 30 to 40.

In what Science magazine has dubbed “Novo Nordisk’s Canadian Mistake,” Ozempic is soon to come off patent in Canada, opening ...

Ozempic could cut the risk of dementia by half, a University of Oxford study has suggested. Scientists set out to establish the impact of the weight-loss jab on the brain in the first study of its ...

GLP-1 medications offer promising benefits for obesity and diabetes patients, with studies showing reduced heart attack risk and potential applications for addiction treatment.

“According to the latest figures released by the NHS, dementia diagnosis is at a record high in England. “This is great news for residents, as increased awareness results in increased ...

Newly published research claims those taking GLP-1 jabs are at a 37 percent lower risk of dementia than those on the ...

Semaglutide — the active ingredient in type 2 diabetes and weight-loss glucagon-like peptide-1 agonist ( GLP-1) medications Ozempic and Wegovy — may help lower dementia risk, a new study finds.

Results from this study show that there is a direct correlation between the use of anti-obesity medications and testosterone levels,” the study author said.

Odds are you’ve heard of GLP-1 drugs like Ozempic for managing type 2 diabetes and shedding pounds. But have you ever wondered what Ozempic does to your brain? Recent research suggests it might ...

A new study of 60,000 people around the world is shedding light on the possible brain health benefits of popular weight-loss ...

Semaglutide — the active ingredient in type 2 diabetes and weight-loss glucagon-like peptide-1 agonist ( GLP-1) medications Ozempic and Wegovy — may help lower dementia risk, a new study finds.